0.00Open0.85Pre Close0 Volume71 Open Interest210.00Strike Price0.00Turnover52.57%IV10.63%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.85Extrinsic Value100Contract SizeAmericanOptions Type-0.0619Delta0.0071Gamma492.67Leverage Ratio-0.1388Theta-0.0027Rho-30.48Eff Leverage0.0400Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet